Researchers from the VA Ann Arbor Healthcare System (VAAAHS) and the University of Michigan Health System highlight the importance of taking an individualized approach when it comes helping people with diabetes minimize their risks for heart disease.
Like aspirin, metformin is one of those drugs that over the years keeps proving itself beneficial in ways it wasn’t originally intended to be.
For patients with type 2 diabetes inadequately controlled by metformin alone, addition of the new oral anti-diabetes agent imeglimin improves glycemic control with good tolerability and safety, according to a study published online Nov. 16 in Diabetes Care.
In the last 10 years, new types of diabetes medications have resulted in improved diabetes control. Diabetes incretins are among those newer medications that are proving to be very effective. As you probably know, untreated Type 2 diabetes can be fatal.
Treating obese children at risk for type 2 diabetes with the diabetes drug metformin was shown to be safe and effective.
A major cause of hypoglycemia is excess sulfonylurea administration – taking a common medication without eating, or taking too much of it. Many, many trips to the emergency department arise from trouble with sylfonylurea meds.
A new drug for type 2 diabetes, involving research at Aston University is being launched as a once-daily tablet for adults with the condition.
The latest medication for people with type 2 diabetes is Bydureon, revealed early this year 2012.
The eye drug Lucentis (ranibizumab injection), approved in August to treat diabetic macular edema, may also be useful in people with diabetic retinopathy, according to research
People living with diabetes may be able to reduce the risk of developing depression and other mood disorders by including a common medication in the management of their condition.
An FDA-approved drug initially used to treat insulin resistance in diabetics has shown promise as a way to improve cognitive performance in some people with Alzheimer’s disease.
This new insulin is far better than existing insulins available in the market both in terms of efficacy and safety. It is an ultra long acting drug with a half life of 25 hours.
They include 32 new treatments for type 1 diabetes, 130 for type 2, 14 for unspecified diabetes and 64 for diabetes-related conditions, says PhRMA, which describes this pipeline as “an exciting new chapter in the ongoing quest to better treat this debilitating disease.”
To compare the effects of metformin and sulfonylureas on cardiovascular outcomes such as heart attack, stroke, and death, researchers looked at the charts of more than 250,000 veterans receiving health care at Veterans Health Administration hospitals across the United States.
FORXIGA is a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2) that works independently of insulin to help remove excess glucose from the body, a unique mode of action not seen in any other currently available treatments.
“Studies show that older beta- blockers can increase a patient’s risk of type 2 diabetes by more than 25 percent.” While raising the risk of diabetes is not good for anyone, it is especially damaging for individuals who already have conditions that affect the heart and vascular system.
Yesterday, the FDA’s Endocrinologic & Metabolic Drug Advisory Committee voted to recommend approval for degludec, a new long acting insulin for the treatment of type 1 and type 2 diabetes.
Patients with diabetes who were treated with the popular oral medication metformin face a lower risk of heart attack, stroke or death than those taking sulfonylureas, another common option, according to a large, multi-year study.
A direct, head-to-head comparison of two of the newer treatments available for type 2 diabetes yielded mixed results.
These pharmacist-recommended over-the-counter products will make your next trip to the drugstore easier. Scroll down to find recommendations for diabetics.